Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation.
Fuchs KJ, Göransson M, Kester MGD, Ettienne NW, van de Meent M, de Jong RCM, Koster EAS, Halkes CJM, Scheeren F, Heemskerk MHM, van Balen P, Falkenburg JHF, Hadrup SR, Griffioen M. Fuchs KJ, et al. Among authors: koster eas. J Immunother Cancer. 2024 Dec 9;12(12):e009564. doi: 10.1136/jitc-2024-009564. J Immunother Cancer. 2024. PMID: 39653555 Free PMC article.
Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS, von dem Borne PA, van Balen P, van Egmond EHM, Marijt EWA, Veld SAJ, Jedema I, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, de Wreede LC, Halkes CJM. Koster EAS, et al. Transplant Cell Ther. 2023 Apr;29(4):268.e1-268.e10. doi: 10.1016/j.jtct.2022.12.022. Epub 2022 Dec 30. Transplant Cell Ther. 2023. PMID: 36587743 Free article.
Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.
Koster EAS, Bonneville EF, Borne PAVD, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Putter H, Falkenburg JHF, Halkes CJM, de Wreede LC. Koster EAS, et al. Front Immunol. 2023 Aug 1;14:1208814. doi: 10.3389/fimmu.2023.1208814. eCollection 2023. Front Immunol. 2023. PMID: 37593737 Free PMC article.
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
Fuchs KJ, van de Meent M, Honders MW, Khatri I, Kester MGD, Koster EAS, Koutsoumpli G, de Ru AH, van Bergen CAM, van Veelen PA, 't Hoen PAC, van Balen P, van den Akker EB, Veelken JH, Halkes CJM, Falkenburg JHF, Griffioen M. Fuchs KJ, et al. Among authors: koster eas. Blood. 2024 May 2;143(18):1856-1872. doi: 10.1182/blood.2023022343. Blood. 2024. PMID: 38427583 Free PMC article.
Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity.
Laghmouchi A, Kester MGD, Hoogstraten C, Hageman L, de Klerk W, Huisman W, Koster EAS, de Ru AH, van Balen P, Klobuch S, van Veelen PA, Falkenburg JHF, Jedema I. Laghmouchi A, et al. Among authors: koster eas. Front Immunol. 2022 Feb 16;13:831822. doi: 10.3389/fimmu.2022.831822. eCollection 2022. Front Immunol. 2022. PMID: 35251023 Free PMC article.
Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients.
van der Zouwen B, Koster EAS, von dem Borne PA, Oosten LEM, Roza-Scholten MWI, Snijders TJF, van Lammeren D, van Balen P, Marijt WAF, Veelken H, Falkenburg JHF, de Wreede LC, Halkes CJM. van der Zouwen B, et al. Among authors: koster eas. Ann Hematol. 2023 May;102(5):1203-1213. doi: 10.1007/s00277-023-05145-1. Epub 2023 Mar 7. Ann Hematol. 2023. PMID: 36881136 Free PMC article.
Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing.
Huisman W, Roex MCJ, Hageman L, Koster EAS, Veld SAJ, Hoogstraten C, van Balen P, van Egmond HM, van Bergen CAM, Einsele H, Germeroth L, Amsen D, Falkenburg JHF, Jedema I. Huisman W, et al. Among authors: koster eas. Blood Adv. 2023 Mar 14;7(5):812-827. doi: 10.1182/bloodadvances.2022007270. Blood Adv. 2023. PMID: 36121440 Free PMC article.
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.
Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LC. Bakunina K, et al. Among authors: koster eas. Cancer Med. 2022 Feb;11(3):630-640. doi: 10.1002/cam4.4392. Epub 2021 Dec 24. Cancer Med. 2022. PMID: 34953042 Free PMC article. Clinical Trial.
Excess mortality during the first 2 years of the COVID-19 pandemic (2020-2021) in the Netherlands: Overall and across demographic subgroups.
Caram-Deelder C, Vlieg AVH, Groenwold RHH, Chen Q, Mook-Kanamori DO, Dekkers OM, Koster EAS, de Wreede LC, van Nieuwkoop C, Toshkov DD, Rosendaal FR. Caram-Deelder C, et al. Among authors: koster eas. IJID Reg. 2024 Nov 27;14:100500. doi: 10.1016/j.ijregi.2024.100500. eCollection 2025 Mar. IJID Reg. 2024. PMID: 39830316 Free PMC article.
12 results